SUMMARY -Th e aim was to compare the effi cacy of a single intravitreal injection of perfl uoropropane (C3F8) and sulfur hexafl uoride (SF6) in releasing vitreomacular traction (VMT). Th is prospective study included two groups of patients with symptomatic VMT confi rmed by spectral-domain optical coherence tomography (SD-OCT). Patients from both groups received a single intravitreal injection of expansile gas. One group (29 eyes) received 0.3 mL of 100% C3F8, and the other group (28 eyes) received 0.3 mL of 100% SF6. Eyes without VMT release one month after SF6 injection were secondarily injected with C3F8. Th e primary outcome was the ratio of eyes in each group with complete VMT release on OCT one month following primary treatment. Th e secondary outcome was the ratio of reinjected eyes with complete VMT release on OCT one month following second injection. Additional outcome was the ratio of VMT release in eyes with specifi c clinical characteristics. One month after the application, complete release of VMT on OCT was recorded in 18 out of 29 eyes (62%) in the C3F8 group, in 6 out of 28 eyes (21.4%) in the SF6 group, and in 7 out of 14 (50%) reinjected eyes. Th ere was no statistically signifi cant diff erence in age, width of vitreomacular attachment (WVMAT), central retinal thickness and presence of additional features between the two groups. In eyes with WVMAT <500 microns, there was no statistically signifi cant diff erence between the two gases in releasing VMT. In eyes with WVMAT >500 microns, C3F8 was more effi cacious (p=0.001). According to the results of our study, intravitreal C3F8 injection seems to be more effi cacious in releasing VMT than SF6 in eyes with WVMAT larger than 500 microns.
Introduction
Vitreoretinal interface diseases are thought to occur due to an anomalous or incomplete posterior vitreous detachment (PVD), i.e. separation of the vitreous cortex from the internal limiting membrane. In 2013, the International Vitreomacular Traction Study Group defi ned and classifi ed vitreoretinal interface diseases according to optical coherence tomography (OCT)-based anatomic fi ndings in vitreomacular adhesion (VMA), vitreomacular traction (VMT) and macular hole 1 . VMA was defi ned as perifoveal vitreous separation with the remaining vitreomacular attachment and unperturbed foveal morphological features. It is an OCT fi nding that is almost always the result of normal vitreous aging 1 . VMT is characterized by anomalous posterior vitreous detachment accompanied by anatomic distortion of the fovea, which may include pseudocysts, macular schisis, cystoid macular edema, and subretinal fl uid 1 . Primary full-thickness macular hole (FTMH) was defi ned as a foveal lesion with in-terruption of all retinal layers from the internal limiting membrane to the retinal pigment epithelium, caused by vitreous traction 1 . Anatomical changes of the fovea induced by VMT can lead to typical symptoms of reduced visual acuity, decreased reading vision, metamorphopsia, and micropsia. Th e natural history of patients with VMT is not well established, but it is thought that 11%-40% of symptomatic VMT dissolve spontaneously in 8-12 months, although restoration of foveal anatomy is uncertain 2 . Other symptomatic patients with persistent VMT may undergo further progression into macular hole, persistent macular edema, foveal detachment, macular atrophy, and severe deterioration of visual function and quality of life [3] [4] [5] . Th e standard treatment for severe VMT is pars plana vitrectomy. Th e goal of vitreous surgery is to eliminate anteroposterior and tangential traction, thereby relieving attachment of the vitreous to the macula. Vitreolysis is achieved in 100% of cases, with good anatomical outcome and some improvement of vision in most cases 6 , but the surgery itself is not without risk. Intraoperative retinal tears occur in up to 1.6% and postoperative retinal detachment in up to 7 . Since 2012, ocriplasmin has been approved as a non-surgical, pharmacologic agent for the treatment of symptomatic VMT, but vitreolysis is only achieved in 25%-50% 8, 9 , with a high incidence of side eff ects 8 and at a high cost. In the last years, pneumatic vitreolysis has started to show promise as a new treatment option for VMT.
In the past two decades, there have been quite a few studies investigating the effi cacy of a single intravitreal gas injection in causing PVD in eyes with different pathologies, such as nonproliferative diabetic retinopathy 10 , diabetic macular edema 11 , stage II macular holes 12 , and wet macular degeneration 13 . Th e success rate was 95%-100% with very few complications.
Recently, at least three small case studies investigated pneumatic vitreolysis also in eyes with VMT. Rodrigues et al. demonstrated that a single intravitreal injection of perfl uoropropane (C3F8) could cause VMT resolution in 5/7 (70%) eyes with isolated VMT and in 3/6 (50%) eyes with concurrent diabetic macular edema 14 . Th ere were no complications. Day et al. obtained VMT release in 5/9 (55.6%) patients after a single intravitreal injection of sulfur hexafl uoride (SF6). A peripheral retinal tear occurred in one patient (11%), and no other complications were noted 15 . In a study more recently published by Steinle et al., complete release after intravitreal injection of up to 0.3 mL of 100% C3F8 occurred in 25 out of 30 eyes (83%) with symptomatic VMT. Th ey had the same success rate in eyes with concurrent epiretinal membrane (ERM) (5 out of 6 eyes, 83%) and in eyes previously treated with ocriplasmin (5 out of 6 eyes, 83%) 16 . According to these studies, a single intravitreal gas injection seems to be effi cacious in causing PVD and could therefore be a promising treatment option for VMT with a high success rate and very high safety profi le. However, the total number of patients and the power of studies were rather low. In most of the studies, either SF6 or C3F8 was used, and hexafl uoroethane (C2F6) was also used in one study 17 . Table 1 presents specifi c and combined success rates achieved in the studies using SF6 or C3F8. SF6 was used in a total of 29 eyes and PVD was obtained in 78% of cases. C3F8 was used in 93 eyes in total, with PVD occurring in 83% of cases.
According to these studies, intravitreal SF6 and C3F8 injections seem to be almost equally effi cacious in causing PVD, even though they have diff erent specifi c qualities. A pure SF6 bubble expands to about double the volume injected within 24 to 48 hours, and stays in the eye for 1 to 2 weeks. A pure C3F8 bubble expands to about 4 times its original volume within 72 to 96 hours, and persists in the vitreous cavity for 6 to 8 weeks. Since SF6 is reabsorbed from the vitreous much faster and it is much less of a burden for the patient, we wanted to check whether, despite its lower expansibility, it is really as eff ective in releasing VMT as C3F8.
Th e purpose of our study was to directly compare the effi cacy of intravitreal injections of SF6 and C3F8 in causing PVD, and additionally to evaluate the visual acuity success rate after pneumatic PVD in patients with VMT.
Patients and Methods
Th is prospective comparative study included 57 eyes of consecutive patients aged 57-91 years with symptomatic VMT and primary FTMH stage II. Patient enrolment and treatment took place at the Eye Hospital of the University Medical Center Ljubljana. Preoperatively and postoperatively, the routine comprehensive ophthalmological examination (including best corrected visual acuity (BCVA) using Snellen charts, biomicroscopy and funduscopy) and spectral domain OCT (SD-OCT) of the macula were performed with Heidelberg Spectralis in all patients.
Th e width of vitreomacular attachment (WV-MAT), central retinal thickness (CRT), integrity of external limiting membrane (ELM) and ellipsoid zone, and the presence of ERM were noted. Postoperatively, we looked for the presence of PVD; restoration of foveal contour and CRT were noted.
Th e inclusion criteria were any symptomatic VMT with deterioration of visual acuity of at least 2 Snellen lines and the duration of symptoms for at least 3 months (or less if the deterioration was very rapid, at least 2 or more Snellen lines in 0.5 months), and primary FTMH stage II according to Gass.
Th e only exclusion criterion were completely disrupted outer retinal layers on OCT.
Twenty-nine eyes from the C3F8 group received a single intravitreal injection of 0.3 mL of 100% C3F8, and 28 eyes from the SF6 group received a single intravitreal injection of 0.3 mL of 100% SF6. Th e gas was injected in an operating theatre under sterile conditions. Paracentesis with aqueous humor leakage was performed right after the injection to release the intraocular pressure. No medications were used intra-or postoperatively. Patients were then asked to nod their head occasionally in the next few days and/or hold prone position for a few consecutive minutes 5-10 times a day. Follow-up visits were performed at week 1, month 1, month 3 and month 6 after the injection.
Eyes from the SF6 group that showed no PVD on SD-OCT one month after the injection were reinjected with 0.3 mL of 100% C3F8. Th ey were followed by the same protocol.
Th e primary outcome was the ratio of eyes with complete VMT release on SD-OCT one month following the primary injection. Th e secondary outcome was the ratio of reinjected eyes with complete release on SD-OCT one month after the second injection.
Additional outcomes were the ratio of VMT release in eyes with diff erent WVMAT, CRT, integrity of external ELM, ellipsoid zone, and the presence of ERM.
T-test was used to compare preoperative characteristics of the C3F8 and SF6 groups (age, WVMAT and CRT). Th e χ 2 -test was used to compare VMT release after one month between the C3F8 and SF6 groups and between the subgroups with specifi c clinical characteristics.
Results
Th ere was no statistically signifi cant diff erence in age, WVMAT and CRT, or the presence of additional features between the two groups ( Table 2) .
One month after the application, complete release of VMT on SD-OCT was recorded in 18 out of 29 eyes (62%) in the C3F8 group and in 6 out of 28 eyes (21.4%) in the SF6 group, yielding a statistically signifi cant diff erence (p=0.003). In the reinjected group, complete release of VMT demonstrated by SD-OCT one month after reinjection was recorded in 7 out of 14 eyes (50%) (Fig. 1) .
Most of the eyes with VMT release from both groups had VMT release already in the fi rst week (12 out of 18 (66.6%) eyes from the C3F8 group and 5 out of 6 (83.3%) eyes from the SF6 group). In the reinjected group, PVD was noted after 1 week in only 2 out of 7 (28.6%) eyes. In this group, another eye showed VMT release at the month 3 visit. No other 
Fig. 1. Vitreomacular traction (VMT) release one month after gas injection.
VMT release was noted in the additional 3-month follow-up period in either group. In 4 eyes with preoperative stage II primary FTMH (160-310 microns, mean 223 microns) from the C3F8 group, VMT release occurred in 4/4 (100%) eyes. In one eye (25%), the hole closed; its size was 160 microns. Th e other three patients proceeded to surgery; the hole was successfully closed after fi rst vitrectomy. Table 3 shows the ratio of VMT release in groups of eyes with specifi c clinical characteristics. Th e efficacy in VMT release in narrower WVMAT was similar in both groups; however, intravitreal C3F8 injection was more effi cacious than SF6 in releasing VMT in eyes with WVMAT larger than 500 microns (p=0.001). In the ERM subgroup, VMT release was present in 2/10 (20%) eyes after C3F8 and in none after SF6 injection.
3.6%). Th ree patients proceeded to vitrectomy, in all the retina was attached and macular hole closed after fi rst vitrectomy. One patient declined the operation. No other signifi cant complications were observed.
Discussion
In our group of eyes, complete VMT release was achieved in 62% of eyes with a single intravitreal injection of 0.3 mL of 100% C3F8 and with the same volume of 100% SF6 only in 21.4% of eyes. Since there was no statistically signifi cant diff erence in the preoperative features between the two gas groups, this result alone implies that C3F8 is more effi cacious in releasing VMT than SF6. Obtaining PVD with secondary intravitreal C3F8 injection in 50% of eyes that failed to respond to primary injection with SF6 backs up this implication.
Analyzing the eff ect of the two gases on VMT release according to WVMAT, C3F8 and SF6 were equally eff ective in the narrower width of attachment (<500 microns, p=0.4410), while C3F8 was much more eff ective than SF6 in releasing VMT in the group with greater WVMAT (>500 microns, p=0.001). It also seemed to be more successful in eyes with ERM; with the intravitreal injection of SF6 we did not achieve a single release in this subgroup.
According to the literature, our study that included 57 eyes seems to be the largest one investigating pneumatic vitreolysis so far. It was also the fi rst study directly comparing the effi cacy of the two gases (SF6 and C3F8). Th e number of eyes was large enough to prove that C3F8 in general was superior to SF6 in releasing VMT and equally eff ective in narrower WVMAT.
Comparison of our results and those reported from other studies investigating pneumatic vitreolysis in eyes with diff erent pathologies [10] [11] [12] [13] [14] [15] [16] reveals that we had a lower overall PVD rate with either gas injection. In these studies, PVD was achieved in 56%-100% (mean 78%) with SF6 and in 40%-100% (mean 83%) with C3F8. Th is may be due to the less narrow patient selection in our study; the included patients were consecutively recruited patients that met the inclusion criteria notwithstanding the WVMAT or any of the additional features. Certain clinical characteristics such as patient age 11, 15, 16 and phakic/pseudophakic ratio 15, 16 were, to our knowledge, similar to other studies, Considering complications, there was a peripheral retinal tear with localized retinal detachment in one eye and a small FTMH with a diameter of 220 microns in another eye seen one week after C3F8 injection. After one month, another eye with a macular hole of 330 microns was found in this group (complication rate: 3/29 eyes, 10.3%). A small macular hole with a diameter of 225 microns was also found in one eye from the SF6 group at one-week follow-up (1/28 eyes, but unfortunately, many of the previous studies failed to provide data on WVMAT and presence of ERM, so these characteristics could not be compared.
Th e reason for this PVD success rate diff erence may as well lie in the lower number of patients in previous studies or in diff erent vitreoretinal pathology. It is reasonable to believe that the strength of adhesion in eyes with VMT is much fi rmer than in eyes with VMA (which by defi nition is without vitreal traction) and could therefore explain the lower rate of pneumatically induced PVD in eyes with VMT. When comparing our results only with those from the studies investigating eyes with VMT [14] [15] [16] , we were equally eff ective, at least with C3F8. PVD rate in those studies was 40%-84% (mean 61.5%), whereas in ours it was 62%.
Day et al. obtained PVD in 56% of eyes with VMT with the intravitreal injection of SF6 15 , compared to our 21.4%, but they had only 9 eyes and in all 5 eyes with postoperative PVD WVMAT was less than 521 microns and none had ERM.
In our study, C3F8 appeared to be superior to SF6 also in the subgroup with ERM but the numbers were too small to prove it statistically signifi cant. Our results are comparable to previous studies, even though the number of eyes included in those studies was also very low. Day et al. had 2 eyes with ERM, and none had PVD after intravitreal SF6 15 . On the other hand, Steinle et al. had 6 eyes with ERM and achieved PVD in 5 of those with intravitreal C3F8 16 . In our study, 4 eyes with primary stage II FTMH (160-310 microns, mean 223 microns) were included in the C3F8 group. PVD was obtained in 4/4 (100%) eyes, but only in one the hole closed (25%). Its size was 160 microns, while the size of the hole in the remaining three eyes was >200 microns. All patients with the remaining hole proceeded to surgery and the hole was successfully closed after fi rst vitrectomy.
Steinle et al. had 3 stage II FTMH; in 2 (66.6%), the hole closed after PVD 16 . Mori et al. had similar success 12 ; they had 20 patients with stage II FTMH, in 50% the hole closed after PVD. Th e size of the hole in all patients from both studies was less than 200 microns. Concluding from these data, the size of the hole being less than 200 microns may be an important prognostic factor for hole closure after successful pneumatic PVD in primary stage II FTMH.
Most of our patients from the SF6 group presented with a very small bubble or even no gas at all at the fi rst follow-up (week 1). In all these eyes, gas was absent at the second follow-up (month 1). On the contrary, in most patients from the C3F8 group, gas was fi lling up to one-third of their vitreal cavity at the fi rst follow-up and in all at least a small bubble was present at the second follow-up. Unlike the SF6 patients, patients that received C3F8 were complaining immensely about the gas bubble interference with their vision. Th ey reported having troubles walking down the stairs, preparing their meals and reading. However, what they found most annoying, some of them even completely unbearable, was the duration of troubles. Th e average time for PVD to appear after the injection was 13 days in the study by Steinle et al. 16 . Since also in our study more than 60% of eyes with VMT release had PVD already one week after the injection, it seems that the effi cacy of C3F8 might be more due to the expandability rather than its persistence. We wonder would the results have been diff erent also in the subgroups with ERM or larger attachments if we had used 0.5 mL of 100% SF6 instead. Th e maximum expanded volume would then match that of C3F8 and might therefore exert the same eff ect, but with the advantage of faster clearance from the eye.
Ochoa-Contreras et al. 10 used 0.5 mL of SF6 in their study on patients with nonproliferative diabetic retinopathy with a PVD success rate of 100%, but they had no ERM and unfortunately data on WVMAT are not provided in the published article.
Since according to previous studies and our own, it can now be said with certainty that gas injection is suffi ciently eff ective in causing VMT release in eyes with WVMAT smaller than 1000 microns and in the absence of epiretinal membrane, we believe that due to its seemingly high safety profi le, low cost and easy accessibility, it would seem reasonable in certain situations to at least try it as a fi rst line treatment in VMT patients that meet the above criteria. Th e waiting time for vitrectomy as a traditional way of treatment in some parts of the world exceeds six months. Postponing treatment for such a long time can result in photoreceptor damage and irreversible vision loss. Th e costs of vitrectomy vary in diff erent countries and hospitals, but generally amount to several hundred Euros. Intravitreal gas injection, on the other hand, can be applied at an offi ce visit in just a few minutes and at minimal cost.
We suggest using SF6 in eyes with WVMAT smaller than 500 microns and C3F8 in those with WVMAT larger than 500 microns.
Conclusion
According to the results of our study, intravitreal C3F8 injection appears to be as effi cacious as SF6 in releasing smaller vitreomacular attachment and more effi cacious in releasing larger vitreomacular attachment in eyes with VMT.
